Supplementary

Table S1 Meta-analysis of miR-193b as a prognostic indicator for patients of various carcinoma without outliers

Variables	No. of studies	No. of patients	Pooled HR (95% CI)		Meta regression	Heterogeneity	
			Fixed	Random	P value	I^2	P value
Overall	8	733	0.56 (0.46, 0.69)	0.45 (0.30, 0.69)	–	72.20%	0.001
Population					0.503		
Asian	7	572	0.59 (0.47, 0.74)	0.45 (0.28, 0.74)		75.00%	0.001
Caucasian	1	161	0.43 (0.25, 0.72)	0.43 (0.25, 0.72)		–	–
Sample size					0.212		
≥100	3	383	0.39 (0.27, 0.55)	0.39 (0.27, 0.56)		4.00%	0.353
<100	5	350	0.67 (0.52, 0.87)	0.51 (0.28, 0.92)		76.40%	0.002
NOS scores					0.339		
≥8	2	267	0.44 (0.30, 0.67)	0.44 (0.30, 0.67)		0.00%	0.811
<8	6	466	0.61 (0.48, 0.77)	0.45 (0.25, 0.80)		78.70%	0.001
Tumor category 1					0.206		
Non-digestive system carcinoma	3	376	0.35 (0.24, 0.52)	0.35 (0.24, 0.52)		0.00%	0.467
Digestive system carcinoma	5	357	0.68 (0.53, 0.86)	0.54 (0.31, 0.92)		74.70%	0.003
Tumor category 2					0.351		
Non-urogenital system carcinoma	6	518	0.62 (0.50, 0.78)	0.52 (0.33, 0.82)		76.70%	0.003
Urogenital system carcinoma	2	215	0.28 (0.16, 0.50)	0.28 (0.16, 0.50)		0.00%	0.491

95% CI, 95% confidence interval; Fixed, fixed model; HR, hazard ratio; NOS, Newcastle-Ottawa scale scores; Random, random model.

Table S2 Summary of publication bias in various analyses

Variables	No. of studies	No. of patients	Begg's test (P value)	Egger's test (P value)
Pooling HR with outliers	10	1,015	1.000	0.199
Pooling HR without outliers	8	733	0.902	0.116
Pooling HR for multivariate regression analysis	4	411	0.734	0.380
Pooling OR for gender	5	536	0.086	0.017
Pooling OR for ages	2	153	1.000	–
Pooling OR for tumor sizes	3	312	1.000	0.742
Pooling OR for lymph node metastasis	4	359	0.734	0.322

HR, hazard ratio; OR, odds ratio.

© Translational Cancer Research. All rights reserved.
https://dx.doi.org/10.21037/tcr-21-2557



Figure S1 Sensitivity analyses for HRs of (A) overall survivals without outliers, (B) multivariate regression analysis, and the association between miR-193b levels and (C) gender, (D)tumor size, (E) lymph node metastasis, (F) distant metastasis.

© Translational Cancer Research. All rights reserved.
https://dx.doi.org/10.21037/tcr-21-2557



Figure S2 Clinicopathology characteristics analyses including publication bias for association analysis of miR-193b expression levels and (A) gender, (B) distant metastasis; forest plots for association between miR-193b expression levels and (C) gender without the outlier, (D) distant metastasis without the outlier.

© Translational Cancer Research. All rights reserved.
https://dx.doi.org/10.21037/tcr-21-2557